Saturday, April 20, 2024

Medtronic Diabetes Launches MiniMed™ 780G System: World’s First Approval for an All-in-One

Similar articles

Medtronic plc, a global leader in healthcare technology, has achieved a significant milestone with the CE Mark for diabetes management approval for the MiniMed™ 780G system, integrated with the Simplera Sync™ sensor. This new development represents a major advancement in diabetes management technology, offering a disposable, all-in-one continuous glucose monitor (CGM) that simplifies the process of monitoring glucose levels for diabetes patients.

Key Highlights of the MiniMed™ 780G System with Simplera Sync™

  1. Innovative CGM Technology: The Simplera Sync™ is a disposable, all-in-one CGM that requires no fingersticks or overtape, enhancing the user experience with a simple, two-step insertion process. It is half the size of previous Medtronic sensors, making it more convenient and less intrusive for users.
  2. Availability in Europe: The MiniMed 780G system with Simplera Sync™ sensor will initially be available in Europe through a limited release in spring 2024, followed by a phased commercial launch in summer 2024. The MiniMed™ 780G system is currently compatible with the Guardian™ 4 sensor.
  3. Advanced Insulin Delivery System: The MiniMed™ 780G system is Medtronic’s most advanced system, automatically adjusting and correcting glucose levels every 5 minutes. It includes a Meal Detection™ feature designed to reduce post-meal hyperglycemia and offers one of the lowest glucose target settings of any automated insulin delivery system.
  4. Enhanced Diabetes Management: The system alleviates the burden of counting carbohydrates and dosing insulin, particularly beneficial for those who may underestimate their carb intake. This feature is crucial in preventing prolonged hyperglycemia, which can lead to serious health complications.
  5. User Experience and Real-World Data: Medtronic’s MiniMed™ 780G system is widely used in Europe, with real-world data showing an average Time in Range of nearly 80%. The new Simplera Sync™ sensor can be applied in under 10 seconds, offering comfort and ease of use.
  6. Indications and Compatibility: The system is indicated for ages 7 and above and is compatible with both iOS and Android platforms. However, the Simplera Sync™ sensor is not yet approved by the FDA and is limited to investigational use in the U.S.
  7. Integration with Advanced AID Algorithm: The Simplera Sync™ sensor leverages Medtronic’s advanced AID algorithm as part of its MiniMed™ 780G system. It maintains a similar look and feel to the Simplera™ CGM, which was integrated with the InPen™ smart insulin pen and received CE Mark in September 2023.Diabetes

MiniMed™ 780G System with Simplera Sync™ Sensor Revolutionizing Diabetes Management

In conclusion, the approval of the MiniMed™ 780G system with Simplera Sync™ sensor marks a significant innovation in diabetes care. This system not only offers advanced glucose monitoring and insulin delivery options but also improves the quality of life for diabetes patients by simplifying daily management routines. With its smaller size, ease of use, and advanced features, the MiniMed™ 780G system with Simplera Sync™ sensor is set to transform diabetes management in Europe and potentially globally, once it receives broader regulatory approvals.

 

Resource: Medtronic, January 09, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article